PDCD1 and glioblastoma: Although immune checkpoint blockades (ICBs), such as anti-PD-1 (aPD-1) therapy, have shown efficacy against multiple tumors, their effect on GBM has been disappointing (2), and recent clinical trials of ICBs for GBM have failed (3).